Cart
sales@molnova.com
Sofalcone
CAS No. 64506-49-6
Sofalcone( SU-88 )
Catalog No. M19821 CAS No. 64506-49-6
Sofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 33 | In Stock |
|
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 75 | In Stock |
|
| 1G | 109 | In Stock |
|
Biological Information
-
Product NameSofalcone
-
NoteResearch use only, not for human use.
-
Brief DescriptionSofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.
-
DescriptionSofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.(In Vitro):Sofalcone (50 μmol/L) significantly increases HO-1 mRNA expression compare with the control group in both trophoblasts and HUVECs (P<0.05 for both). Western blot analysis demonstrates that Sofalcone potently increases HO-1 protein expression in primary HUVECs treated for 24 hours. Western blot analysis also reveals a significant increase in the amount of Nrf2 in the nuclear fraction of HUVECs with Sofalcone treatment (50 μmol/L) for 6 hours. In primary HUVECs, expression of NQO1, TXN, and GCLC are increased in a dose dependently manner with Sofalcone treatment for 24 hours. Sofalcone significantly decreases the sFlt-1 concentrations in the culture media and dose dependently decreases the amount of THP-1 monocyte adherence to HUVECs.
-
In VitroSofalcone (50 μmol/L) significantly increases HO-1 mRNA expression compare with the control group in both trophoblasts and HUVECs (P<0.05 for both). Western blot analysis demonstrates that Sofalcone potently increases HO-1 protein expression in primary HUVECs treated for 24 hours. Western blot analysis also reveals a significant increase in the amount of Nrf2 in the nuclear fraction of HUVECs with Sofalcone treatment (50 μmol/L) for 6 hours. In primary HUVECs, expression of NQO1, TXN, and GCLC are increased in a dose dependently manner with Sofalcone treatment for 24 hours. Sofalcone significantly decreases the sFlt-1 concentrations in the culture media and dose dependently decreases the amount of THP-1 monocyte adherence to HUVECs.
-
In Vivo——
-
SynonymsSU-88
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorHeme oxygenase-1
-
Research AreaInflammation/Immunology
-
Indicationgastroenteritis and ulcers
Chemical Information
-
CAS Number64506-49-6
-
Formula Weight450.52
-
Molecular FormulaC27H30O6
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC\C(C)=C\COc1ccc(\C=C\C(=O)c2ccc(OC\C=C(\C)C)cc2OCC(O)=O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
MK-8719
MK-8719 is a highly potent and selective inhibitor of O-GlcNAcase (OGA) (hOGA, Ki=7.9 nM) .
-
LYN-1604 2HCl 221675...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604, to be the best candidate for a ULK1 agonist.?LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.
-
MitoSOX Red
MitoSOX Red is a novel fluorescent probe that is specific and cell membrane-permeable and targets mitochondria in living cells.MitoSOX Red is oxidized by superoxide upon entry into the mitochondria and is not oxidized by other ROS or RNS-generating systems.
